Short Report: Polymorphisms in the pfcr t and pfmdr1 Genes of Plasmodium falciparum and in Vitro Susceptibility to Amodiaquine and Desethylamodiaquine

Diego F. Echeverry,* Gabrielle Holmgren, Claribel Murillo, Juan C. Higuita, Anders Björkman, Jose P. Gil, and Lyda Osorio

International Center for Medical Research and Training (CIDEIM), Cali, Colombia; Malaria Research Unit, Department of Infectious Diseases, Division of Medicine, Karolinska Institute, Stockholm, Sweden

Abstract. The potential role of polymorphisms in the pfcr t and pfmdr1 genes and in vitro susceptibility to amodiaquine and desethylamodiaquine were explored in 15 chloroquine-resistant Colombian Plasmodium falciparum isolates. Single nucleotide polymorphisms in the pfcr t gene, including a newly reported mutation (S334N), were seen in isolates with decreased susceptibility to amodiaquine and desethylamodiaquine. The lowest susceptibility found to amodiaquine was observed in an isolate carrying a pfcr t and pfmdr1 Dd2-like haplotype, whereas a pfcr t haplotype related to the 7G8 Brazilian strain was found in a Colombian isolate with the lowest susceptibility to desethylamodiaquine. This exploratory study suggests that polymorphisms in the pfcr t and pfmdr1 genes play a role in amodiaquine and desethylamodiaquine resistance and warrants further study.

The development and expansion of resistance to the mainstay antimalarials chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) are the major causes for the increased morbidity and mortality of P. falciparum. In response to the increasing morbidity and mortality of P. falciparum, in vitro susceptibility to chloroquine (CQ) and other antimalarial drugs is widely monitored. The development of resistance to antimalarials often leads to the use of combination therapy to treat malaria, which is more effective in many cases. Resistance and therapeutic failures have been observed in areas where CQ and SP are recommended as first-line therapy. The combination of CQ and SP has been used in many countries, including Colombia, and is widely advocated as first-line therapy.

Amodiaquine (AQ) is an antimalarial drug that is widely used in combination with SP in many countries. AQ is absorbed quickly in the gastrointestinal tract and metabolized in the liver by the cytochrome P450 isoform CYP2C8. Its main metabolite is desethylamodiaquine (DEAQ), which seems to exert the main antimalarial effect because of its significantly longer elimination half-life.

Several polymorphisms in two P. falciparum genes, pfcr t and pfmdr1, have been associated with resistance to 4-aminoquinoline antimalarial drugs. Mainly pfcr t 76T, but also pfmdr1 86Y, have been involved in the development of CQ resistance and has also been associated with therapeutic failures after AQ treatment in Sudan, Kenya, and Nigeria. In Colombia, where CQ-resistant P. falciparum is widespread but a more varied response to AQ has been found, the pfcr t 76T allele seems to be present and ubiquitous, whereas the pfmdr1 86Y allele seems to be rare.

In vitro studies have shown that probably through the PFcr T protein, the Ca2+-transporter inhibitor drug verapamil (VP) may sensitize P. falciparum to AQ. In vitro susceptibility mechanisms against AQ/DEAQ, we analyzed the relationship of pfcr t and pfmdr1 mutations in 15 Colombian P. falciparum isolates with their in vitro susceptibility to CQ, AQ, and DEAQ. Documented in vitro data from four P. falciparum reference strains (Dd2, HB3, 3D7, and 7G8) were also included in the analysis as comparators.

The 15 P. falciparum culture adapted isolates, collected between 1999 and 2001 in three endemic areas along the Colombian Pacific Coast, were analyzed in a radioisotopic in vitro susceptibility assay for their response to CQ, AQ, and DEAQ. The isolates were defrosted, adapted to continuous culture in supplemented RPMI-1640, and synchronized with sorbitol. Ninety-six-well plates were coated with 50–3,200 nmol/L CQ and 5–320 nmol/L AQ and DEAQ after a 2-dilution factor (AQ and CQ were provided by the World Health Organization and DEAQ by the Walter Reed Army Institute). The final concentration of [3H]hypoxanthine was 0.5 µCi/well and that of Albumax I was 0.5%. The samples were incubated at 37°C for 48 hours, and each assay was done in duplicate. The counts per minute (cpm) were measured in a scintillation counter (LS7500; Beckman Instruments, Palo Alto, CA), and the IC50s were calculated using the PROBIT program in SPSS 7.5 for Windows 98 (SPSS, Chicago, IL).

The capacity of VP (V4629-1G; Sigma, St. Louis, MO) to sensitize P. falciparum to CQ, AQ, and DEAQ was tested in the isolates TA7519, CA2855, and Dd2 strain, according to the recently developed ELISA-histidine rich protein II (HRP2)–based assay. In vitro cultured parasites were diluted to an initial parasitemia of 0.05% and aliquoted into microculture 96-well plates pre-dosed with ascending concentrations of 16–2,020 nmol/L CQ, 2–270 nmol/L AQ, and 6–780 nmol/L DEAQ ± VP 0.8 µmol/L. After incubation at 37°C for 72 hours, the samples were freeze-thawed, transferred, and processed in pre-coated ELISA plates (Cellabs, New South Wales, Australia) for spectrophotometric analysis (Multiskan EX; Thermo Labsystems, Helsingfors, Finland) of parasite growth. The IC50 values were determined using HN-NonLin V1.05 Beta H. Noedl 2001 (http://malaria.farch.net). All samples were done in quadruple.
For the full sequencing of the \textit{pfcr} gene, total RNA and cDNA were obtained with Trizol LS (Invitrogen, Carlsbad, CA) and SUPERSCRIPT II RT (Invitrogen), respectively. Using the sequence of the HB3 strain (GenBank no. AF233068), primers were designed to amplify three overlapping fragments representing the complete \textit{pfcr} sequence (first block of 437 bp, second block of 409 bp, and third block of 593 bp). After a nested polymerase chain reaction (PCR) strategy, all blocks were sequenced (ABI 3700 Capillary DNA Sequencer; Cybergene AB, Huddinge, Sweden) and bioinformatically analyzed (Chromas V2.75, BLAST, Translate, LALIGN, and Clustal W). For the \textit{pfmdr1} single nucleotide polymorphism (SNP) analysis, a PCR-restriction fragment length polymorphism (RFLP) strategy\(^{26}\) was used to identify SNPs in positions N86Y, F184Y, S1034C, D1042N, and D1246Y (more details about these strategies can be requested from the authors). For the quantification of the \textit{pfmdr1} gene copy number, a TaqMan real-time PCR-based protocol (Applied Biosystems, Fresno, CA) was used as published elsewhere.\(^{27}\) Copy numbers were rounded to the nearest integer. This study was approved by the Ethical committees of CIDEM and Universidad del Valle in Cali, Cali, Colombia.

In all 15 Colombian isolates, the IC\(_{50}\) values for CQ (114.58–415.53 nmol/L, data not shown) were above the WHO recommended cut-off for \textit{in vitro} CQ resistance (IC\(_{50}\) > 100 nmol/L). More variations in IC\(_{50}\) values were observed for both DEAQ (38.31–355.8 nmol/L; Figure 1) and AQ (9.63–64.61 nmol/L; Figure 2). VP was able to considerably decrease the IC\(_{50}\) values in Dd2, CA2855, and TU7519 for CQ from 340.1 to 129.7; 636.9 to 182.3; and 551.7 to 70.9 nmol/L for each sample, respectively. Similarly, VP reduced the IC\(_{50}\) values for DEAQ from 32 to 12.8; 119.7 to 26.6; and 62.9 to 12.2 nmol/L, respectively. In contrast, VP did not modify the \textit{in vitro} response to AQ: 13.1 to 11.0; 26.5 to 28.5; and 22.5 to 22.2 nmol/L, respectively.

DNA sequencing of the \textit{pfcr} gene was completely successful in 12 of 15 samples. Three samples were uncertain in the 371 position. A total of 15 SNPs in 12 positions in the \textit{pfcr} gene were identified (Figures 1 and 2). All 15 Colombian isolates carried the 76T and 220S mutant haplotype. In codons 72–76 of the \textit{pfcr} gene, the CVMET haplotype was seen in 13 of 15 isolates. The isolate TU741 carried a CVMNT haplotype, which has also been found in Ecuador and Peru.\(^{10,28}\) The isolate CA2855 showed a CVIET Dd2-like haplotype extending the reports of the presence of this Southeast Asian CQ-resistant haplotype in South America.\(^{10,28}\) The SVMNT haplotype characteristic of the 7G8 CQ-resistant strain from Brazil and reported in \textit{P. falciparum} populations from Papua New Guinea,\(^{29}\) which has been proposed to be associated with DEAQ resistance,\(^{30}\) was not detected in any Colombian sample.

The SNP 97Q that to this date has been only reported in Colombia was found in the majority (13/15) of the parasites.\(^{10,17}\) In the TU741 isolate, a not previously described SNP, 334N, was identified. The SNP 333S was found in two isolates (TA4640 and TA6182); this SNP was previously found in Cambodia.\(^{31}\) In summary, we identified four \textit{pfcr} haplotypes among the fully sequenced samples (amino acids 72, 74–76, 97, 220, 271, 326, 333, 334, 356, and 371; SNPs are underlined): C\textit{MET}Q\textit{SQ}\textit{NT}\textit{S}T (8/12), C\textit{MET}Q\textit{SQ}\textit{SS} (2/15).

\textbf{Figure 1.} \textit{In vitro} susceptibility to desethylamodiaquine and genetic profile in the \textit{pfcr} and \textit{pfmdr1} genes of \textit{P. falciparum} reference strains and Colombian isolates. SNPs are shadowed. NS; no sequence data.
Three pfmdr1 haplotypes (amino acids 86, 184, 1034, 1042, and 1246) were identified: NFSDD (6/15), NFSDY (8/15), and YYSND (1/15). All tested Colombian isolates had one pfmdr1 gene copy (Figures 1 and 2).

The high IC\textsubscript{50} values for CQ and the more varying IC\textsubscript{50} values for AQ and DEAQ, as well as the presence of pfcrt 76T and 220S in all Colombian samples, are in line with the high level of CQ resistance and the more various therapeutic response to AQ in Colombia. The VP results with sensitization for CQ and DEAQ but not for AQ confirm previously published data\textsuperscript{18,19} and suggest a mechanism of response to AQ less dependent on the pfcrt gene compared with DEAQ.

The TU741 isolate showed the highest IC\textsubscript{50} value for DEAQ (355.8 nmol/L) and the second highest for AQ (41 nmol/L). TU741 was the only isolate with a pfcr 72-76 CVMNT haplotype. TU741 also showed several genetic alterations not present in any of the other studied Colombian isolates, namely the pfcr 326D and 356L SNPs also seen in the clone 7G8 (pfcr 72-76 SVMNT), with the second highest IC\textsubscript{50} value for DEAQ (229,3 nmol/L), as well as pfmdr1 334N. This suggests that the haplotypes pfcr 72-76 SVMNT/ CVMNT, 326D, 334N, and 356L might be associated with DEAQ resistance. The CA2855 isolate showed the highest IC\textsubscript{50} for AQ (64.6 nmol/L) and the third highest to DEAQ (198.1 nmol/L). It was the only isolate carrying a Dd2-like SNP haplotype in both pfcr and pfmdr1. However, CA2855 did have one copy of pfmdr1 compared with three in Dd2 (Figure 2). In addition, CA2855 was identified as FC27 and Dd2 as IC1 families in the msp2 gene (data not shown).

The presence of pfmdr1 86Y, 184Y, and 1042N in this isolate is consistent with recent in vivo data from Kenya where pfmdr1 86Y was selected among recrudescent infections but not among new re-infections after AQ monotherapy,\textsuperscript{12} suggesting that this haplotype is a potential factor for AQ resistance. However, Dd2 with the same haplotype had a lower IC\textsubscript{50} value for AQ. Maybe this difference can be explained by its multicopied pfmdr1 gene or other genes involved in AQ resistance.

A visual analysis of the sequence data along with the IC\textsubscript{50} values of DEAQ (Figure 1) and AQ (Figure 2) showed an accumulation of SNPs in the 3’ region of the pfcr open reading frame (ORF). There was also a tendency of the pfmdr1 1246Y SNP toward higher IC\textsubscript{50} values for AQ. A decrease in the hydrophobicity, volume of lateral chains of the amino acids, and changes in the charges of the PFCRT protein have been predicted to explain the mechanism by which these SNPs could decrease the efficacy of AQ.\textsuperscript{30}

This exploratory study supports the hypothesis that AQ and DEAQ resistance might be associated with different combinations of polymorphisms in the pfcr and pfmdr1 genes. The pfmdr1 copy number seems not be involved in 4-aminoquinolines resistance, which should be explored further.
Financial support: This work was supported by an anonymous Swiss foundation.

Authors’ addresses: Diego F. Echeverry, International Center for Medical Research and Training (CIDEM), Avenida 1 Norte 3-03, Cali, Colombia. Telephone: 572-6682164, Fax: 572-6672989. Gabrielle Holmgren, Malaria Research Lab, M9/02, Karolinska Hospital, Stockholm 17176, Sweden. Claribel Murillo, International Center for Medical Research and Training (CIDEM), Avenida 1 Norte 3-03, Cali, Valle, Colombia, Telephone: 572-6682164, Fax: 572-6672989. Juan C. Higuita, Universidad Nacional de Colombia, Manizales. Departamento de Ingeniería Química, Manizales, Colombia. Anders Bjornman, Malaria Research Lab, M9/02, Karolinska Hospital, Stockholm 17176, Sweden. Jose P. Gil, Malaria Research Lab, M9/02, Karolinska Hospital, Stockholm 17176, Sweden. Lyda Osorio, International Center for Medical Research and Training (CIDEM), Avenida 1 Norte 3-03, Cali, Colombia, Telephone: 572-6682164, Fax: 572-6672989.

REFERENCES


